FLJ16779: A Potential Drug Target and Biomarker (G100192386)

Target Name: FLJ16779

NCBI ID: G100192386

FLJ16779

Other Name(s): Uncharacterized LOC100192386 | uncharacterized LOC100192386

FLJ16779: A Potential Drug Target and Biomarker

FLJ16779 is a protein that is expressed in various tissues and cells of the human body. Its exact function is not yet fully understood, but it is known to be involved in a variety of cellular processes. Based on this information, FLJ16779 may be a potential drug target or biomarker for a variety of diseases.

One of the key functions of FLJ16779 is its role in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. FLJ16779 is involved in the formation of tight junctions, which are the weakest type of cell adhesion, and in the disruption of tight junctions during cell division.

FLJ16779 is also involved in the regulation of cell signaling pathways. It has been shown to be involved in the signaling pathway known as the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival. FLJ16779 has been shown to play a role in the regulation of TGF-β signaling by interacting with the protein SMAD4.

FLJ16779 is also involved in the regulation of inflammation. It has been shown to be involved in the regulation of the immune response by interacting with the protein PDGF-BB. This interaction between FLJ16779 and PDGF-BB suggests that FLJ16779 may be involved in the regulation of inflammation.

In addition to its involvement in cellular processes, FLJ16779 may also be a potential biomarker for a variety of diseases. For example, it has been shown to be involved in the development and progression of certain types of cancer. Additionally, it has been shown to be involved in the regulation of brain function, which suggests that it may be involved in the development and progression of neurological diseases.

Given the potential involvement of FLJ16779 in cellular processes and its involvement in the regulation of disease, it is a promising candidate for further study as a potential drug target or biomarker. Further research is needed to fully understand its functions and to determine its potential as a drug target or biomarker.

Protein Name: Uncharacterized LOC100192386

The "FLJ16779 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FLJ16779 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets